文献速递神经肿瘤

基于多参数MRI的临床-影像组学模型鉴别泌乳素瘤与高泌乳素血症性无功能垂体腺瘤

Multiparameter MRI-based clinical-radiomic model to differentiate prolactinoma from hyperprolactinemic nonfunctioning pituitary adenoma.
PubMed 文献 · J Neurosurg · 2025-11-07

本研究回顾性纳入203例中度高泌乳素血症患者(泌乳素瘤113例,无功能垂体腺瘤90例),构建融合影像组学模型及整合年龄、性别、血清泌乳素水平的临床-影像组学模型。临床-影像组学模型在训练集、验证集及外部多中心验证集的AUC分别为0.94、0.93、0.90,显示出高敏感性和优异鉴别性能。

要点

  • 临床-影像组学模型可无创鉴别泌乳素瘤与无功能垂体腺瘤。
  • 模型整合年龄、性别和血清泌乳素水平,外部验证AUC达0.90。
  • 决策曲线分析提示模型具有显著临床适用性。

核心结论

  • 临床-影像组学模型在鉴别伴高泌乳素血症的泌乳素瘤与无功能垂体腺瘤方面表现出高敏感性和优异性能。

研究设计与样本

  • 回顾性研究纳入203例中度高泌乳素血症患者(泌乳素瘤113例,无功能垂体腺瘤90例),分为训练集和验证集,并采用其他中心32例患者进行外部验证。

主要发现

  • 融合影像组学模型基于3个显著影像组学特征构建,训练集AUC为0.900,验证集AUC为0.890。
  • 临床-影像组学模型整合融合影像组学模型与3个临床特征(年龄、性别、血清泌乳素水平),训练集、验证集、外部多中心验证集AUC分别为0.94、0.93、0.90。
  • 决策曲线分析表明模型对泌乳素瘤和无功能垂体腺瘤患者具有显著临床适用性。

临床怎么用

  • 模型可用于治疗前无创鉴别泌乳素瘤与无功能垂体腺瘤,辅助制定个体化诊疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: It is crucial to differentiate between prolactinoma and nonfunctioning pituitary adenoma (NFPA) prior to treatment because their preferred therapeutic approaches differ. The optimal treatment for NFPA causing compressive symptoms is transsphenoidal surgical debulking, whereas most prolactinomas respond favorably to dopamine agonist therapy. Both can manifest as hyperprolactinemia; however, existing guidelines solely rely on measurement of the serum prolactin level, which has been proven insufficient. The aim of this study was to distinguish prolactinoma and NFPA with moderate hyperprolactinemia using a clinical-radiomic model before treatment. METHODS: A total of 203 patients (174 female, median age 33.0 years) with moderate hyperprolactinemia were diagnosed with prolactinoma (n = 113) or NFPA (n = 90) and divided into training and validation sets retrospectively. An elastic net algorithm was used to screen radiomic features, leading to the establishment of a fusion radiomic model. Subsequently, a clinical-radiomic model was developed by integrating the radiomic model with the significant clinical features for individualized predictions. The calibration, discrimination, and clinical applicability of the models were evaluated. Additionally, the performance of the final selection model was validated using a dataset of 32 patients from other centers. RESULTS: The fusion radiomic model was developed using 3 significant radiomic features, achieving areas under the curve (AUCs) of 0.900 in the training set and 0.890 in the validation set. The clinical-radiomic model was created by integrating the fusion radiomic model with 3 additional clinical features (age, sex, and serum prolactin level). This model demonstrated excellent recognition and calibration capabilities, with AUCs of 0.94, 0.93, and 0.90 in the training, validation, and external multicenter validation sets, respectively. The decision curve analysis indicated that the constructed models had substantial clinical applicability for patients with prolactinoma and NFPA. CONCLUSIONS: Our clinical-radiomic model exhibited high sensitivity and exceptional performance in the differential diagnosis of prolactinoma and NFPA with hyperprolactinemia. This model offers significant potential for the noninvasive development of personalized diagnostic and treatment strategies for individuals with these conditions.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Fan Y, Tao C, Feng M, et al. Multiparameter MRI-based clinical-radiomic model to differentiate prolactinoma from hyperprolactinemic nonfunctioning pituitary adenoma. J Neurosurg. 2025. PMID: 41202296. doi:10.3171/2025.6.JNS25579

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。